APLS
Apellis Pharmaceuticals Inc
Price:  
17.42 
USD
Volume:  
1,583,654.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

Apellis EV/EBITDA

-266.2%
Upside

As of 2025-07-08, the EV/EBITDA ratio of Apellis Pharmaceuticals Inc (APLS) is -12.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apellis's latest enterprise value is 2,284.37 mil USD. Apellis's TTM EBITDA according to its financial statements is -186.25 mil USD. Dividing these 2 quantities gives us the above Apellis EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 11.7x - 13.7x 13.0x
Forward P/E multiples 18.7x - 33.4x 25.0x
Fair Price (28.41) - (21.00) (28.95)
Upside -263.1% - -220.5% -266.2%
17.42 USD
Stock Price
(28.95) USD
Fair Price

Apellis EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2025-07-07 -12.26
2025-07-03 -12.83
2025-07-02 -12.53
2025-07-01 -12.57
2025-06-30 -12.19
2025-06-27 -12.27
2025-06-26 -12.93
2025-06-25 -12.92
2025-06-24 -13.07
2025-06-23 -12.40
2025-06-20 -12.45
2025-06-18 -12.49
2025-06-17 -12.49
2025-06-16 -12.86
2025-06-13 -13.22
2025-06-12 -13.51
2025-06-11 -13.51
2025-06-10 -13.72
2025-06-09 -13.59
2025-06-06 -13.52
2025-06-05 -13.40
2025-06-04 -13.00
2025-06-03 -13.21
2025-06-02 -13.43
2025-05-30 -11.93
2025-05-29 -12.26
2025-05-28 -11.85
2025-05-27 -11.91
2025-05-23 -12.28
2025-05-22 -12.51
2025-05-21 -12.26
2025-05-20 -13.00
2025-05-19 -12.43
2025-05-16 -12.29
2025-05-15 -11.55
2025-05-14 -11.78
2025-05-13 -12.17
2025-05-12 -12.33
2025-05-09 -12.18
2025-05-08 -12.53
2025-05-07 -12.65
2025-05-06 -13.41
2025-05-05 -13.99
2025-05-02 -14.24
2025-05-01 -14.06
2025-04-30 -13.47
2025-04-29 -12.80
2025-04-28 -12.63
2025-04-25 -12.31
2025-04-24 -12.35